Bespoke Extracts (BSPK) Total Non-Current Liabilities (2017 - 2018)
Bespoke Extracts (BSPK) reported Total Non-Current Liabilities of $81153.0 for Q3 2018, down 57.99% on a YoY basis from $193163.0 in Q3 2017, and up 11.02% sequentially from $73098.0 in Q2 2018.
Bespoke Extracts (BSPK) Total Non-Current Liabilities (2017 - 2018) Analysis & Trends
Bespoke Extracts (BSPK) has 2 years of Total Non-Current Liabilities data on file, last reported at $81153.0 in Q3 2018.
- For the quarter ending Q3 2018, Total Non-Current Liabilities fell 57.99% year-over-year to $81153.0; the trailing twelve-month figure through Aug 2018 stood at $81153.0 (down 57.99% YoY), and the FY2018 full-year result was $81153.0, down 57.99% from the prior year.
- Total Non-Current Liabilities climbed to $81153.0 in Q3 2018, from $73098.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $322893.0 in Q1 2018 to a low of $73098.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2018 | 81,153.00 |
| May 31, 2018 | 73,098.00 |
| Feb 28, 2018 | 322,893.00 |
| Nov 30, 2017 | 279,494.00 |
| Aug 31, 2017 | 193,163.00 |